Glucocorticoid-induced Osteoporosis - 24/11/15
Doi : 10.1016/j.rdc.2015.08.005
Xena Whittier, MD a, Kenneth G. Saag, MD, MSc b, ⁎ 
a Division of Clinical Immunology and Rheumatology, 851 Faculty Office Tower, 510 20th Street South, Birmingham, AL 35294, USA
b Division of Clinical Immunology and Rheumatology, Department of Medicine, Center for Education and Research on Therapeutics (CERTs), Center for Outcomes, Effectiveness Research and Education (COERE), Center of Research Translation (CORT) in Gout and Hyperuricemia, University of Alabama at Birmingham, 820 Faculty Office Tower, 510 20th Street South, Birmingham, AL 35294, USA
∗Corresponding author.
Résumé |
Glucocorticoid-induced osteoporosis (GIOP) is one of the most common and serious adverse effects associated with glucocorticoid use. This article highlights GIOP pathophysiology, epidemiologic associations, effective treatment, and lifestyle modifications that can reduce fracture risk for long-term glucocorticoid users and additionally emphasizes the importance of early intervention.
Le texte complet de cet article est disponible en PDF.Keywords : Glucocorticoids, Osteoporosis, Fracture risk, Prevention
Plan
| Conflict of Interest: Consultant with Amgen, Lilly Merck. Research/Grant with Amgen, Lilly, Merck (Dr K.G. Saag). |
© 2016
Elsevier Inc. Tous droits réservés.
Vol 42 - N° 1
P. 177-189 - février 2016 Retour au numéro
Article précédent
- Infection Risk and Safety of Corticosteroid Use
- Jameel Youssef, Shannon A. Novosad, Kevin L. Winthrop
- Index
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?